Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experienceArmon Azizi, Tian Yi Zhang, William Shomali et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 29
Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair VariantsShyam A. Patel, Sigurdís Haraldsdóttir, Teri A. Longacre et al.|The Oncologist|2018Cited by 8